Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C11H12N2O2
Numéro CAS:
Poids moléculaire :
204.23
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12352209
EC Number:
200-194-9
MDL number:
Beilstein/REAXYS Number:
86199
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderNom du produit
DL-Tryptophan, ≥99% (HPLC)
Quality Level
assay
≥99% (HPLC)
form
powder
reaction suitability
reaction type: solution phase peptide synthesis
mp
289-290 °C (dec.) (lit.)
application(s)
peptide synthesis
SMILES string
NC(Cc1c[nH]c2ccccc12)C(O)=O
InChI
1S/C11H12N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9,13H,5,12H2,(H,14,15)
InChI key
QIVBCDIJIAJPQS-UHFFFAOYSA-N
General description
DL-Tryptophan also known as 2-amino-3-(1H-indol-3-yl)-propionic acid, is commonly used in peptide synthesis.
Application
DL-Tryptophan is used as a starting material for the preparation of N-acyl monoisotripeptides via solution-phase peptide synthesis.
Classe de stockage
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Solution-phase synthesis of chiral N-, O-, and S-acyl isopeptides
S Liaqat
Synthesis, 46, 67-72 (2014)
Helen Ling et al.
Movement disorders : official journal of the Movement Disorder Society, 30(7), 960-967 (2015-04-10)
Glial cytoplasmic inclusions containing α-synuclein are the pathological hallmark of multiple system atrophy (MSA). Minimal change (MC-MSA) is an unusual MSA subtype with neuronal loss largely restricted to the substantia nigra and locus coeruleus. Immunohistochemistry on selected brain regions and
Aristeidis Chiotellis et al.
Molecular pharmaceutics, 11(11), 3839-3851 (2014-07-06)
As a continuation of our research efforts toward the development of tryptophan-based radiotracers for tumor imaging with positron emission tomography (PET), three new fluoroethoxy tryptophan analogues were synthesized and evaluated in vivo. These new tracers (namely, 4-(2-[(18)F]fluoroethoxy)-dl-tryptophan ([(18)F]4-FEHTP), 6-(2-[(18)F]fluoroethoxy)-dl-tryptophan ([(18)F]6-FEHTP)